UNSPSC 51352310: Estrazinol

This classification denotes a selective estrogen receptor modulator with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KLU2E3573. The term ESTRAZINOL ACETONIDE is an International Non-Proprietary Name or INN. European Medicines Agency schedules estrazinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07248MIG. Most nations schedule estrazinol under HS 29372300 and SITC 54153. As of Q4 2014, ESTRAZINOL remains the US FDA Preferred Term for this commodity.

Estrazinol bears US NLM identifiers UMLS ID C2348469 and NCI Concept Code C72767. SMILES: CC12CCC3C4=C(CCN3C1CCC2(C#C)O)C=C(C=C4)OC.

UNSPSC 51352310 Estrazinol is a Commodity code that captures pharmaceutical procurement by state and local health and human services agencies, though recent activity shows estrazinol specifically appearing in a broad multi-source generic pharmaceuticals and OTC products cooperative purchasing framework rather than as a standalone line item. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary vehicle observed for this code, sourcing generic drugs and over-the-counter medications for distribution across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must maintain manufacturing compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, hold contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and offer flexible pricing models including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. Insurance requirements include $5 million commercial general liability per occurrence, $2 million network security and privacy liability, and $2 million professional liability.

The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with proposals due March 26, 2026 and questions closing February 18, 2026. Award is expected to be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026 for a two-year term with optional extensions through June 30, 2028 for incumbents. Evaluation emphasizes price competitiveness at 75 percent weight, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. No specific set-aside designations were identified in the available documentation. Submissions are processed through Minnesota's ePro procurement system using Google Chrome, with pricing and product information in designated Excel-to-CSV format.